HRP20191586T1 - Konjugati agensa aktivni na proteine i postupak pripreme istih - Google Patents
Konjugati agensa aktivni na proteine i postupak pripreme istih Download PDFInfo
- Publication number
- HRP20191586T1 HRP20191586T1 HRP20191586T HRP20191586T1 HR P20191586 T1 HRP20191586 T1 HR P20191586T1 HR P20191586 T HRP20191586 T HR P20191586T HR P20191586 T1 HRP20191586 T1 HR P20191586T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- active agent
- agent
- group
- amino acid
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims 26
- 238000000034 method Methods 0.000 title claims 9
- 125000000524 functional group Chemical group 0.000 claims 26
- 102000004357 Transferases Human genes 0.000 claims 13
- 108090000992 Transferases Proteins 0.000 claims 13
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 6
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 5
- 150000001299 aldehydes Chemical class 0.000 claims 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 238000006911 enzymatic reaction Methods 0.000 claims 4
- 150000002576 ketones Chemical class 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 150000001540 azides Chemical class 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 102000004225 Cathepsin B Human genes 0.000 claims 2
- 108090000712 Cathepsin B Proteins 0.000 claims 2
- 102000053187 Glucuronidase Human genes 0.000 claims 2
- 108010060309 Glucuronidase Proteins 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- -1 aliphatic amino acid Chemical class 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 229930182480 glucuronide Natural products 0.000 claims 2
- 150000008134 glucuronides Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- MJYFVDNMTKLGTH-UHFFFAOYSA-N 4-bromo-6-(3,4-dichlorophenyl)sulfanyl-1-[[4-(dimethylcarbamoyl)phenyl]methyl]indole-2-carboxylic acid Chemical compound BrC1=C2C=C(N(C2=CC(=C1)SC1=CC(=C(C=C1)Cl)Cl)CC1=CC=C(C=C1)C(N(C)C)=O)C(=O)O MJYFVDNMTKLGTH-UHFFFAOYSA-N 0.000 claims 1
- ZCVAGTPWBAZXAL-UHFFFAOYSA-N 4-nitro-2,1,3-benzoxadiazole Chemical compound [O-][N+](=O)C1=CC=CC2=NON=C12 ZCVAGTPWBAZXAL-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 229940125687 antiparasitic agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012650 click reaction Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 150000007857 hydrazones Chemical class 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 150000002923 oximes Chemical class 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (13)
1. Konjugat aktivnog sredstva protutijela, naznačen time, da antitijelo ima motiv aminokiseline koji se može prepoznati izoprenoid transferazom, pri čemu je aktivno sredstvo kovalentno vezano za antitijelo na motivu aminokiseline, pri čemu je aminokiselinski motiv CAAX, XXCC XCXC, ili CXX, pri čemu C predstavlja cistein, A predstavlja alifatsku aminokiselinu, a X predstavlja amino kiselinu koja određuje supstratnu specifičnost izoprenoid transferaze;
i pri čemu je aminokiselinski motiv kovalentno vezan na aktivno sredstvo preko najmanje jednog linkera, pri čemu je najmanje jedan linker izoprenilni derivat koji se može prepoznati izoprenoid transferazom, pri čemu je linker predstavljen formulom (I):
pri čemu su P1 i Y svaki nezavisno skupina koja sadržava prvu funkcionalnu skupinu (FG1), FG1 je odabran iz skupine koju čine: acetilen, azid, aldehid, hidroksilamin, hidrazin, keton, nitrobenzofurazan (NBD), danzil, fluorescein, biotin i Rodamin,
L1 je (CH2)rXq (CH2)p,
X je kisik, sumpor, -NR1-, -C(O)NR1-, -NR1C(O)-, -NR1SO2-, -SO2NR1-, -(CH= CH)-,
ili acetilen,
R1 je vodik, C1-6 alkil, C1-6 alkil aril ili C1-6 alkil heteroaril,
r i p su svaki neovisno cijeli broj od 0 do 6,
q je cijeli broj od 0 do 1, i n je cijeli broj od 1 do 4,
pri čemu je aktivno sredstvo vezano na skupinu koja sadržava drugu funkcionalnu skupinu (FG2) koja može reagirati s FG1, pri čemu je FG2 odabran iz skupine koju čine: acetilen, hidroksilamin, azid, aldehid, hidrazin, keton, i pri čemu je aktivno sredstvo vezano na skupinu koja sadržava FG2 preko -(CH2)rXq(CH2)p- ili [ZCH2CH20 (CH2CH20)wCH2CH2Z]-, pri čemu,
X je kisik, sumpor, -NR1-, -C(O)NR1-, -NR1C(O)-, -NR1SO2 ili -SO2NR1-,
Z je kisik, sumpor ili NR1,
R1 je vodik, C1-6 alkil, C1-6 alkil aril ili C1-6 alkil heteroaril,
r i p su svaki neovisno cijeli broj od 0 do 6,
q je cijeli broj od 0 do 1, i w je cijeli broj od 0 do 6,
pri čemu je -(CH2)rXq(CH2)p- ili - [ZCH2CH2O(CH2CH2O)wCH2CH2Z]- vezan za (i) peptid(e) koji se može cijepati pomoću katepsina B ili (ii) glukuronid koji se može cijepati β-glukuronidazom,
pri čemu je peptid koji se može cijepati pomoću katepsina B
i
glukuronid koji se može cijepati s β-glukuronidazom je
i pri čemu je antitijelo monoklonsko antitijelo, fragment ciljnog vezivnog antitijela, jednolančani Fv(scFv) mutant, multispecifično antitijelo, bispecifično antitijelo koje se proizvodi od najmanje dva intaktna antitijela, kimerno antitijelo, humanizirano antitijelo ili ljudsko protutijelo ili fuzijski protein koji sadržava fragment antitijela za ciljno vezanje.
2. Konjugat aktivnog sredstva antitijela u skladu s patentnim zahtjevom 1, naznačen time, da je aktivno sredstvo lijek, toksin, afinitetni ligand, detekcijska sonda, imunomodulatorni spoj, sredstvo protiv raka, anti-virusno sredstvo, anti- bakterijsko sredstvo, anti-gljivično sredstvo ili anti-parazitsko sredstvo.
3. Konjugat aktivnog sredstva antitijela u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da se koristi u terapiji kod subjekta.
4. Konjugat aktivnog sredstva antitijela u skladu s patentnim zahtjevom 3, naznačen time, da subjekt ima rak.
5. Konjugat aktivnog sredstva antitijela u skladu s patentnim zahtjevom 3, naznačen time, da subjekt ima infekciju patogenim agensom.
6. Konjugat aktivnog sredstva antitijela u skladu s patentnim zahtjevom 5, naznačen time, da je patogeni agens virus, bakterija, gljivica ili parazit.
7. Postupak za pripravu konjugata aktivnog sredstva antitijela u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da obuhvaća:
(a) ekspresiju protutijela vezanog za aminokiselinski motiv koji se može prepoznati izoprenoid transferazom;
(b) enzimska reakcija, koristeći izoprenoid transferazu, pri čemu eksprimirano antitijelo s najmanje jednim izosupstratom koji ima prvu funkcionalnu skupinu (FG1), čime se proizvodi funkcionalizirano antitijelo;
(c) povezivanje druge funkcionalne skupine (FG2) s aktivnim sredstvom, čime se proizvodi funkcionalno aktivno sredstvo; i
(d) reakcija funkcionaliziranog antitijela s funkcionaliziranim aktivnim sredstvom, čime se proizvodi konjugat aktivnog sredstva antitijela,
ili
(e) ekspresiju protutijela vezanog za aminokiselinski motiv koji se može prepoznati izoprenoid transferazom;
(f) vezanje izosupstrata izoprenoid transferaze na aktivno sredstvo; i
(g) enzimska reakcija, koristeći izoprenoid transferazu, pri čemu se eksprimirano antitijelo s aktivnim sredstvom veže na izosupstrat.
8. Postupak u skladu s patentnim zahtjevom 7, naznačen time, da postupak obuhvaća:
(a) ekspresiju protutijela vezanog na motiv aminokiseline koji se može prepoznati izoprenoid transferazom;
(b) enzimska reakcija, koristeći izoprenoid transferazu, pri čemu eksprimirano antitijelo s najmanje jednim izosupstratom koji ima prvu funkcionalnu skupinu (FG1) proizvodi funkcionalizirano antitijelo;
(c) povezivanje druge funkcionalne skupine (FG2) s aktivnim sredstvom, čime se dobiva funkcionalno aktivno sredstvo; i
(d) reakcija funkcionaliziranog antitijela s funkcionaliziranim aktivnim sredstvom, čime se proizvodi konjugat aktivnog sredstva antitijela.
9. Postupak u skladu s patentnim zahtjevom 7, naznačen time, da postupak sadržava :
(a) ekspresiju protutijela vezanog na aminokiselinski motiv koji se može prepoznati izoprenoid transferazom;
(b) vezanje izosupstrata izoprenoid transferaze na aktivno sredstvo; i,
(c) enzimska reakcija, koristeći izoprenoid transferazu, pri čemu se eksprimirano antitijelo s aktivnim sredstvom veže na izosupstrat.
10. Postupak u skladu s patentnim zahtjevom 7 ili 8, naznačen time, da je FG2:
(a) vezan na aktivno sredstvo pomoću najmanje jednog veznika, i
(b) FG2 je odabran iz skupine koju čine: acetilen, hidroksilamin, azid, aldehid, hidrazin, keton i amin.
11. Postupak u skladu s bilo kojim patentnim zahtjevom 7 do 10, naznačen time, da je reakcija između funkcionaliziranog antitijela i funkcionaliziranog aktivnog sredstva kemijska reakcija klikova ili stvaranje hidrazona i / ili oksima.
12. Postupak u skladu s patentnim zahtjevom 11, naznačen time, da
(i) FG1 je azidna skupina, a FG2 je acetilenska skupina ili pri čemu je FG1 acetilenska skupina, a FG2 je azidna skupina; ili
(ii) FG1 je aldehidna ili ketonska skupina, a FG2 je hidrazin ili hidroksilamin ili pri čemu je FG1 hidrazin ili hidroksilamin, a FG2 je aldehid ili keton.
13. Pripravak, naznačen time, da sadržava farmaceutski prihvatljivo pomoćno sredstvo i konjugat aktivnog sredstva protutijela iz patentnih zahtjeva 1 ili 2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161483698P | 2011-05-08 | 2011-05-08 | |
EP12782658.4A EP2707031B1 (en) | 2011-05-08 | 2012-05-08 | Protein-active agent conjugates and method for preparing the same |
PCT/IB2012/001065 WO2012153193A2 (en) | 2011-05-08 | 2012-05-08 | Protein-active agent conjugates and method for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191586T1 true HRP20191586T1 (hr) | 2019-12-13 |
Family
ID=47139740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191586 HRP20191586T1 (hr) | 2011-05-08 | 2019-09-04 | Konjugati agensa aktivni na proteine i postupak pripreme istih |
Country Status (22)
Country | Link |
---|---|
US (7) | US20120308584A1 (hr) |
EP (2) | EP2707031B1 (hr) |
JP (2) | JP6196613B2 (hr) |
KR (1) | KR101921068B1 (hr) |
CN (1) | CN103648530B (hr) |
BR (2) | BR122020001787A8 (hr) |
CA (1) | CA2835576C (hr) |
CY (1) | CY1122152T1 (hr) |
DK (1) | DK2707031T3 (hr) |
ES (1) | ES2744226T3 (hr) |
HR (1) | HRP20191586T1 (hr) |
HU (1) | HUE045348T2 (hr) |
IL (2) | IL229364B (hr) |
LT (1) | LT2707031T (hr) |
MX (2) | MX364707B (hr) |
PL (1) | PL2707031T3 (hr) |
PT (1) | PT2707031T (hr) |
RS (1) | RS59253B1 (hr) |
RU (1) | RU2613906C2 (hr) |
SG (1) | SG194875A1 (hr) |
SI (1) | SI2707031T1 (hr) |
WO (1) | WO2012153193A2 (hr) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2707031T3 (pl) | 2011-05-08 | 2020-01-31 | Legochem Biosciences, Inc. | Koniugaty białko-środek czynny i sposoby i ch wytwarzania |
KR102356286B1 (ko) | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
SG11201400770SA (en) * | 2011-09-20 | 2014-04-28 | Spirogen Sarl | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
CN104955485B (zh) * | 2012-10-12 | 2018-01-30 | Adc疗法责任有限公司 | 吡咯并苯并二氮杂卓‑抗her2抗体结合物 |
EP2934596A1 (en) * | 2012-12-21 | 2015-10-28 | Glykos Finland Oy | Linker-payload molecule conjugates |
JP6602746B2 (ja) | 2013-03-15 | 2019-11-06 | カポン、ダニエル・ジェイ. | 非ペプチジル結合を含むハイブリッド免疫グロブリン |
ES2759503T3 (es) | 2013-05-02 | 2020-05-11 | Glykos Finland Oy | Conjugados de una glicoproteína o un glicano con una carga útil tóxica |
FR3008408B1 (fr) | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
WO2015095972A1 (en) * | 2013-12-23 | 2015-07-02 | The Centre For Drug Research And Development | Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof |
SI3701971T1 (sl) | 2014-03-14 | 2023-01-31 | Biomolecular Holdings LLC, | Spojine, uporabne v pripravi hibridnega imunoglobulina, ki vsebuje nepeptidilno vezavo |
KR101628872B1 (ko) * | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
ES2779974T3 (es) | 2014-06-13 | 2020-08-21 | Tenboron Oy | Conjugados que comprenden un anticuerpo anti-egfr1 |
EP3160513B1 (en) | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
US10519248B2 (en) * | 2014-07-25 | 2019-12-31 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
US11820832B2 (en) | 2014-07-25 | 2023-11-21 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
KR20160080832A (ko) * | 2014-12-29 | 2016-07-08 | 주식회사 레고켐 바이오사이언스 | 리피바디 유도체-약물 복합체, 그 제조방법 및 용도 |
CN104587487B (zh) * | 2015-01-06 | 2018-01-16 | 华东师范大学 | 一种应用于靶向给药系统的新的支链连接体 |
CN104650179A (zh) * | 2015-02-06 | 2015-05-27 | 东南大学 | 一种新型的可被溶酶体酶裂解的铂类前药 |
WO2017051254A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-egfr antibody drug conjugates |
WO2017051249A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
CN112451682A (zh) * | 2015-11-25 | 2021-03-09 | 乐高化学生物科学股份有限公司 | 包含自降解基团的缀合物及其相关方法 |
EP3380125A4 (en) * | 2015-11-25 | 2019-08-28 | LegoChem Biosciences, Inc. | CONJUGATES WITH PEPTIDE GROUPS AND RELATED METHODS |
US11173214B2 (en) | 2015-11-25 | 2021-11-16 | Legochem Biosciences, Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
GB201521709D0 (en) * | 2015-12-09 | 2016-01-20 | Kings College London And Sec Dep For Health The | PBD Antibacterial agents |
RS60663B1 (sr) * | 2016-05-17 | 2020-09-30 | Abbvie Biotherapeutics Inc | Konjugati anti-cmet antitelo-lek i metodi za njihovu primenu |
WO2017219025A1 (en) | 2016-06-17 | 2017-12-21 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
CN109803673A (zh) | 2016-09-13 | 2019-05-24 | 阿勒根公司 | 非蛋白质梭菌毒素组合物 |
SI3544634T1 (sl) * | 2016-11-23 | 2021-08-31 | Eli Lilly And Company | Konjugati zdravila s protitelesom proti met |
KR102085798B1 (ko) | 2016-12-28 | 2020-03-06 | 주식회사 인투셀 | 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물 |
CN108250055B (zh) * | 2016-12-28 | 2022-08-05 | 重庆医药工业研究院有限责任公司 | 一种焦磷酸丙酮基香叶酯中间体的制备方法 |
WO2018134787A2 (en) | 2017-01-20 | 2018-07-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd137+ cells |
CA3058360A1 (en) | 2017-03-29 | 2018-10-04 | Legochem Biosciences, Inc. | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same |
AU2018288030B2 (en) * | 2017-06-20 | 2022-02-03 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (TDC) |
WO2019035649A1 (ko) * | 2017-08-14 | 2019-02-21 | 주식회사 레고켐 바이오사이언스 | EGFRvIII에 대한 항체를 포함하는 항체 약물 접합체 |
BR112020022299A2 (pt) | 2018-05-09 | 2021-02-23 | Legochem Biosciences, Inc. | composições e métodos relacionados a conjugados de anticorpo-fármaco anti-cd19 |
KR20200084802A (ko) | 2019-01-03 | 2020-07-13 | 주식회사 레고켐 바이오사이언스 | 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도 |
WO2020141923A2 (ko) | 2019-01-03 | 2020-07-09 | 주식회사 레고켐 바이오사이언스 | 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도 |
EP3936150A4 (en) | 2019-03-06 | 2023-03-29 | LegoChem Biosciences, Inc. | ANTIBODY-DRUG CONJUGATES COMPRISING ANTIBODY AGAINST HUMAN DLK1 AND USE THEREOF |
JP2022530482A (ja) | 2019-05-02 | 2022-06-29 | レゴケム バイオサイエンシズ, インク. | トリス構造を有するリンカーを含むリガンド―薬物複合体 |
KR102501394B1 (ko) * | 2019-05-02 | 2023-02-21 | 주식회사 레고켐 바이오사이언스 | 트리스 구조를 가지는 링커를 포함하는 리간드-약물 접합체 |
KR20210028544A (ko) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
US20230310640A1 (en) | 2019-12-31 | 2023-10-05 | Legochem Biosciences, Inc. | Pyrrolobenzodiazepine derivative and ligand-linker conjugate thereof |
JP2024512324A (ja) | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス,インコーポレイテッド | 抗グリコcd44抗体およびその使用 |
WO2022211508A1 (ko) | 2021-03-30 | 2022-10-06 | 주식회사 레고켐바이오사이언스 | 인간 cldn18.2에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
CA3228178A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
WO2023018199A1 (ko) * | 2021-08-09 | 2023-02-16 | 주식회사 레고켐바이오사이언스 | 신규 항생제 및 이의 용도 |
GB202203070D0 (en) | 2022-03-04 | 2022-04-20 | Iksuda Therapeutics Ltd | Anti-canag antibody conjugate |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US20030129191A1 (en) * | 1992-12-23 | 2003-07-10 | Neorx Corporation | Pretargeting methods and compounds |
DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
US6011175A (en) * | 1993-05-18 | 2000-01-04 | University Of Pittsburgh | Inhibition of farnesyltransferase |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
US20030017149A1 (en) * | 1996-10-10 | 2003-01-23 | Hoeffler James P. | Single chain monoclonal antibody fusion reagents that regulate transcription in vivo |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
AU2001261409A1 (en) * | 2000-05-11 | 2001-11-20 | Oklahoma Medical Research Foundation | Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with NS398 or PDTC |
US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
WO2003059282A2 (en) | 2002-01-09 | 2003-07-24 | Medarex, Inc. | Human monoclonal antibodies against cd30 |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
US8048432B2 (en) * | 2003-08-06 | 2011-11-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
SG195524A1 (en) | 2003-11-06 | 2013-12-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
CA2548180C (en) * | 2003-12-04 | 2014-02-04 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
AU2005205867A1 (en) | 2004-01-21 | 2005-08-04 | Novo Nordisk Health Care Ag | Transglutaminase mediated conjugation of peptides |
TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
US20050266008A1 (en) | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
SV2007002227A (es) | 2004-09-10 | 2007-03-20 | Wyeth Corp | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637 |
JP5061096B2 (ja) | 2005-04-21 | 2012-10-31 | スピロゲン リミティッド | ピロロベンゾジアゼピン |
ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
EP4026840A1 (en) * | 2005-07-18 | 2022-07-13 | Seagen Inc. | Beta-glucuronide-linker drug conjugates |
WO2007030642A2 (en) * | 2005-09-07 | 2007-03-15 | Medimmune, Inc. | Toxin conjugated eph receptor antibodies |
JP2009509510A (ja) | 2005-09-26 | 2009-03-12 | メダレックス インコーポレーティッド | Cd70に対するヒトモノクローナル抗体 |
US20070122408A1 (en) * | 2005-10-20 | 2007-05-31 | The Scripps Research Institute | Fc Labeling for Immunostaining and Immunotargeting |
WO2007112007A2 (en) * | 2006-03-22 | 2007-10-04 | University Of Utah Research Foundation | Immobilized proteins and methods and uses thereof |
JP2009530392A (ja) * | 2006-03-22 | 2009-08-27 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | タンパク質プレニルトランスフェラーゼの阻害剤 |
AU2007333098A1 (en) | 2006-12-14 | 2008-06-19 | Medarex, Inc. | Human antibodies that bind CD70 and uses thereof |
PE20090481A1 (es) * | 2007-07-16 | 2009-05-18 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso |
WO2009026274A1 (en) * | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
WO2009038685A1 (en) | 2007-09-18 | 2009-03-26 | The Scripps Research Institute | Ligands for copper-catalyzed azide-alkyne cycloaddition reactions |
CA2720247C (en) * | 2008-03-31 | 2020-07-14 | Pacific Biosciences Of California, Inc. | Single molecule loading methods and compositions |
GB0813432D0 (en) | 2008-07-22 | 2008-08-27 | Spirogen Ltd | Pyrrolobenzodiazepines |
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
CN102012425A (zh) * | 2010-12-29 | 2011-04-13 | 南开大学 | 一种新的免疫荧光标记方法 |
PL2707031T3 (pl) | 2011-05-08 | 2020-01-31 | Legochem Biosciences, Inc. | Koniugaty białko-środek czynny i sposoby i ch wytwarzania |
KR101628872B1 (ko) * | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
-
2012
- 2012-05-08 PL PL12782658T patent/PL2707031T3/pl unknown
- 2012-05-08 RS RSP20191130 patent/RS59253B1/sr unknown
- 2012-05-08 US US13/466,875 patent/US20120308584A1/en not_active Abandoned
- 2012-05-08 ES ES12782658T patent/ES2744226T3/es active Active
- 2012-05-08 PT PT12782658T patent/PT2707031T/pt unknown
- 2012-05-08 SG SG2013083134A patent/SG194875A1/en unknown
- 2012-05-08 EP EP12782658.4A patent/EP2707031B1/en active Active
- 2012-05-08 MX MX2013013069A patent/MX364707B/es active IP Right Grant
- 2012-05-08 BR BR122020001787A patent/BR122020001787A8/pt not_active Application Discontinuation
- 2012-05-08 KR KR1020137032628A patent/KR101921068B1/ko active IP Right Grant
- 2012-05-08 JP JP2014509854A patent/JP6196613B2/ja active Active
- 2012-05-08 LT LTEP12782658.4T patent/LT2707031T/lt unknown
- 2012-05-08 CA CA2835576A patent/CA2835576C/en active Active
- 2012-05-08 EP EP19182361.6A patent/EP3610889A1/en active Pending
- 2012-05-08 WO PCT/IB2012/001065 patent/WO2012153193A2/en active Application Filing
- 2012-05-08 SI SI201231663T patent/SI2707031T1/sl unknown
- 2012-05-08 BR BR112013028907A patent/BR112013028907A2/pt not_active Application Discontinuation
- 2012-05-08 RU RU2013154264A patent/RU2613906C2/ru active
- 2012-05-08 CN CN201280031480.7A patent/CN103648530B/zh active Active
- 2012-05-08 HU HUE12782658A patent/HUE045348T2/hu unknown
- 2012-05-08 DK DK12782658.4T patent/DK2707031T3/da active
-
2013
- 2013-11-08 MX MX2019001253A patent/MX2019001253A/es unknown
- 2013-11-10 IL IL229364A patent/IL229364B/en unknown
-
2014
- 2014-02-15 US US14/181,648 patent/US20140161829A1/en not_active Abandoned
- 2014-02-15 US US14/181,649 patent/US20140187756A1/en not_active Abandoned
- 2014-10-17 US US14/517,616 patent/US9669107B2/en active Active
-
2016
- 2016-02-26 US US15/054,257 patent/US20160213786A1/en not_active Abandoned
-
2017
- 2017-05-31 JP JP2017107976A patent/JP6385525B2/ja active Active
- 2017-06-02 US US15/612,766 patent/US10583197B2/en active Active
-
2019
- 2019-09-04 HR HRP20191586 patent/HRP20191586T1/hr unknown
- 2019-09-25 CY CY20191101008T patent/CY1122152T1/el unknown
- 2019-10-03 IL IL26980419A patent/IL269804A/en unknown
-
2020
- 2020-03-09 US US16/812,690 patent/US20200289662A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191586T1 (hr) | Konjugati agensa aktivni na proteine i postupak pripreme istih | |
JP6744212B2 (ja) | ポリペプチドの酵素的結合 | |
KR102648564B1 (ko) | 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물 | |
JP2015510761A5 (hr) | ||
US20220088212A1 (en) | C-terminal lysine conjugated immunoglobulins | |
Tsumuraya et al. | Development of a monoclonal antibody against the left wing of ciguatoxin CTX1B: Thiol strategy and detection using a sandwich ELISA | |
EP2872894B1 (en) | Screening of conjugated antibodies | |
JP2019502684A5 (hr) | ||
CN102313801A (zh) | 一种抗体的代谢标记方法及其荧光检测中的应用 | |
JP2024501121A (ja) | 癌の処置 | |
US20130196903A1 (en) | Multimeric Inhibitors of Viral Fusion and Uses Thereof | |
JP2021512599A (ja) | 中東呼吸器症候群コロナウイルスに対して中和活性を有する結合分子 | |
CN110088139A (zh) | 新的生物素特异性单克隆抗体及其用途 | |
US11236386B2 (en) | Method for labeling of aldehyde containing target molecules | |
US20220017462A1 (en) | Ortho-phthalaldehyde containing linkers and use for preparation of antibody-drug conjugate | |
Kang et al. | Highly sensitive and universal detection strategy based on a colorimetric assay using target-specific heterogeneous sandwich DNA aptamer | |
US20210009685A1 (en) | Antibody specifically binding to folr1 and uses thereof | |
JP3714942B2 (ja) | 生物体液中のバンコマイシンの検出および定量化用試薬および方法 | |
CA2721422A1 (en) | Chemical and biochemical adducts as biomarkers for organophosphate exposure | |
Zeng et al. | Development and identification of monoclonal antibodies against parathion | |
CN116621927B (zh) | 带有伊喜替康和C-lock定点偶联基团的抗体偶联中间体、偶联方法及抗体偶联药物 | |
US11054430B2 (en) | Compounds and methods for the detection of methotrexate | |
Bouillé et al. | Molecular analysis of the combining site of a monoclonal antibody against spermine | |
CZ201519A3 (cs) | Makromolekulární konjugáty pro izolaci, imobilizaci a vizualizaci proteinů | |
CA3201005A1 (en) | Glycoside dual-cleavage linkers for antibody-drug conjugates |